Replies to post #24094 on RespireRx Pharmaceuticals Inc (RSPI)

[DewDiligence]

Does that mean that MRK is aware of COR and values it?

You must be joking. Ampakines do not even constitute round-off error in the rationale for the MRK-SGP deal.

[gfp927z]

MarketFest, >>> Doesn't Merck have some Ampakines? <<<

They do now :o)

As far as I know, Merck didn't previously have AMPA upmodulators (unlike Lilly and Glaxo), at least based on their patents. But I remember their neuro head (Dr. Choi?) ~3-4 years ago commented in an interview that he considered AMPA upmodulation one of the more promising areas within the neuro sector. I'm not sure if Choi is still with Merck though.

I'd be interested in Neuro's take on what the change in ownerhip to Merck may mean for Org-26576, and on the timeline for potentially partnering some of Cortex's newer compounds to Schering/Merck. Obviously Merck will have their hands full in integrating the two companies, but at least they'll be reviewing all of Schering's programs, so the Org-26576 ADHD and Depression data will be looked at. The Org-26576 ADHD data should be available this month (based on the info at clinical trials.gov), and the Depression data should have been available since ~ Oct.